Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Susan Duke, Manager, Benefit Risk Evaluation, GSK
Speaker: Andreas Sashegyi, Research Advisor, Decision Sciences Lilly Corporate Center, Lilly
A Benefit-risk Model to Facilitate DMC-sponsor Communication and Decision Making
Drug Information Journal, Vol. 45, pp. 749-757, 2011 Abstract | Paper+ | Slides
PSI Chair: Katherine Hutchinson, Head of Consultancy, Quanticate Speaker: Sara Hughes, VP, Clinical Statistics, GSK
Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial
Sara Hughes, Robert L. Cuffe, Alfons Lieftucht and W. Garrett Nichols
Pharmaceutical Statistics, Vol. 8, Issue 1, pp. 25-37, 2009 Abstract | Paper+ | Slides
Discussant: Lisa LaVange, Director, Office of Biostatistics in the Office of Translational Sciences, FDA
+ Papers available to view from 5th June 2012 to 3rd July 2012.
For a flier advertising the event, please click here.
Joint PSI, EFSPI & ASA BIOP Webinar: Estimands
PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.
Discover your potential by working as a Covance Senior Principal / Principal Biostatistician. You'll enjoy a varied role working for different sponsors across several therapeutic areas, leading projects and mentoring junior members of the department.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.